Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yeon Joo | - |
dc.contributor.author | Tae, Bum Sik | - |
dc.contributor.author | Bae, Jae Hyun | - |
dc.date.accessioned | 2021-08-30T15:40:54Z | - |
dc.date.available | 2021-08-30T15:40:54Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 2093-4777 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/53633 | - |
dc.description.abstract | Special considerations should be made when selecting medications for the treatment of lower urinary tract symptoms (LUTS) in older patients especially those over 65 years old. This review summarizes the relationship between current treatments for LUTS and cognitive impairment. Although the recently reported association between dementia and tamsulosin is debatable, the effects of alpha-blockers and pharmacokinetics are not reported in this context. Five-alpha reductase inhibitors appear to affect mood. However, the association between the development of dementia and cognitive impairment is unlikely. Anticholinergic agents, other than trospium, fesoterodine, and imdafenacin have a relatively high distribution in the central nervous system. In particular, oxybutynin is reported to cause cognitive impairment. Several animal studies on the blood-brain barrier permeability of oxybutynin support this. Therefore, care must be taken when they are used in older patients (65 years and older). Beta-3 agonists are an alternative to, or may be used in combination with, anticholinergic drugs for patients with an overactive bladder (OAB). Several phase 2 and 3 clinical studies report high tolerability and efficacy, making them relatively safe for OAB treatment. However, there is a possibility that cognitive function may be affected; thus, long-term study data are required. We have reviewed studies investigating the correlation of urologic medications with cognitive dysfunction and have provided an overview of drug selection, as well as other considerations in older patients (65 years and older) with LUTS. This narrative review has focused primarily on articles indexed in PubMed, Google Scholar, Scopus, and Embase databases. No formal search strategy was used, and no meta-analysis of data was performed. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CONTINENCE SOC | - |
dc.subject | MUSCARINIC RECEPTOR OCCUPANCY | - |
dc.subject | BENIGN PROSTATIC HYPERPLASIA | - |
dc.subject | OVERACTIVE BLADDER | - |
dc.subject | ALPHA(1)-ADRENOCEPTOR ANTAGONISTS | - |
dc.subject | ALZHEIMERS-DISEASE | - |
dc.subject | OLDER-PEOPLE | - |
dc.subject | LONG-TERM | - |
dc.subject | DETRUSOR HYPERREFLEXIA | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | OXYBUTYNIN | - |
dc.title | Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, Jae Hyun | - |
dc.identifier.doi | 10.5213/inj.2040082.041 | - |
dc.identifier.scopusid | 2-s2.0-85094193685 | - |
dc.identifier.wosid | 000576289000006 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL NEUROUROLOGY JOURNAL, v.24, no.3, pp.231 - 240 | - |
dc.relation.isPartOf | INTERNATIONAL NEUROUROLOGY JOURNAL | - |
dc.citation.title | INTERNATIONAL NEUROUROLOGY JOURNAL | - |
dc.citation.volume | 24 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 231 | - |
dc.citation.endPage | 240 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002631814 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | MUSCARINIC RECEPTOR OCCUPANCY | - |
dc.subject.keywordPlus | BENIGN PROSTATIC HYPERPLASIA | - |
dc.subject.keywordPlus | OVERACTIVE BLADDER | - |
dc.subject.keywordPlus | ALPHA(1)-ADRENOCEPTOR ANTAGONISTS | - |
dc.subject.keywordPlus | ALZHEIMERS-DISEASE | - |
dc.subject.keywordPlus | OLDER-PEOPLE | - |
dc.subject.keywordPlus | LONG-TERM | - |
dc.subject.keywordPlus | DETRUSOR HYPERREFLEXIA | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | OXYBUTYNIN | - |
dc.subject.keywordAuthor | Adrenergic alpha-antagonists | - |
dc.subject.keywordAuthor | 5-Alpha reductase inhibitors | - |
dc.subject.keywordAuthor | Cholinergic antagonists | - |
dc.subject.keywordAuthor | Adrenergic beta-3 agonists | - |
dc.subject.keywordAuthor | Cognitive dysfunction | - |
dc.subject.keywordAuthor | Dementia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.